Other languages Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Market Closed - Japan Exchange Other stock markets 11:30:00 08/05/2024 am IST			5-day change	1st Jan Change
3,975 ^JPY	-0.25%		+0.76%	+11.81%

13/02	LIM Advisors Partially Withdraws Shareholder Proposal	CI
09/02	Torii Pharmaceuticals Opposes Shareholder Proposal	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LIM Advisors Partially Withdraws Shareholder Proposal	13/02
Torii Pharmaceuticals Opposes Shareholder Proposal	09/02
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	15/12
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	12/12
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12/12
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	30/11
LIM Advisors Submits Shareholder Proposal to Torii Pharmaceutials	10/23/10
Japan Tobacco urged to sell drug unit by activist shareholder LIM	20/23/20
Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical After Phase 3 Viral Skin Disease Trial Gets Underway	01/22/01
Torii Pharmaceutical Co., Ltd. Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum	01/22/01
Effissimo Capital Management Submits Shareholder Proposal to Torii Pharmaceutical	06/21/06
BioCryst Pharmaceuticals' : Orladeyo Receives Approval for Japanese NHI Price Listing	14/21/14
Akebia Therapeutics : Obtains Approval For Additional Indication of Riona Tablets in Japan	24/21/24
Verrica Pharmaceuticals : Torii Strike Exclusive Licensing Deal To Develop, Commercialize VP-102 For Molluscum, Common Warts in Japan	17/21/17
Torii Pharmaceutical Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ended December 31, 2019	20/20/20
Japan Tobacco Inc. Revises Earnings Guidance for Fiscal Year Ended December 31, 2019	31/19/31
Japan Tobacco: la rentabilité s'essouffle au 2e trimestre, minée par les changes	31/19/31
Torii Pharmaceutical Co., Ltd. Revises Earnings Guidance for the Year Ending December 31, 2019	31/19/31
Torii Pharmaceutical Co., Ltd. Revises Earnings Guidance for the Year Fiscal Year Ended December 31, 2017	22/18/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Other languages

Filters